Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

José Gorgojo Martínez, Juan; Mezquita‐Raya, Pedro; Carretero‐Gómez, Juana; Castro, Almudena; María Cebrián Cuenca, Ana; de Torres-Sánchez, Alejandra; Dolores García-de-Lucas, María; Núñez, Julio; Carlos Obaya, Juan; José Soler, María; Luis Górriz, José; A. Rubio, Miguel

doi:10.3390/jcm12010145

Public

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Published in Journal of Clinical Medicine • Dec 24, 2022

Authors:

Juan José Gorgojo Martínez

Pedro Mezquita‐Raya

Juana Carretero‐Gómez

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or co...

Subject

Medicine

Nausea

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!